Clinical Trial Update: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Global Phase III trial evaluating Rilvegostomig or pembrolizumab plus chemotherapy as first-line treatment for metastatic squamous non-small cell lung cancer; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING